This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kachra, Z. Articles by Antakly, T. Search for Related Content PubMed PubMed Citation Articles by Kachra, Z. Articles by Antakly, T.

Low Molecular Weight Components But Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi’s Sarcoma Cells

Department of Biochemistry (Z.K., W.-X.G., T.A.), and Molecular Reproduction Laboratory of the Clinical Research Institute (M.R.S.), University of Montréal, Montréal, Canada H3C 3J7

Address all correspondence and requests for reprints to: Tony Antakly, University of Montreal, Pathology Department, C.P. 6128, Succursale A, Montreal, Quebec H3C 3JC, Canada.

Kaposi’s sarcoma, a sexually dimorphic disease inflicting high mortality in AIDS, remains at present without effective treatment. A recent report (Nature 375:64, 1995) showed that the placental glycoprotein hormone, human chorionic gonadotropin (HCG), and surprisingly its ß subunit, inhibit tumorigenicity and metastasis of Kaposi’s sarcoma cells in mice xenografts. The anti-KS efficacy of a commercial HCG was subsequently demonstrated in clinical trials. Experimental data presented herein confirm that commercial HCG preparations (known to be about 25% pure) display significant inhibitory action in a dose-dependent manner. However, pure and biologically active HCG has no effect on Kaposi’s sarcoma growth in culture. In fact, incubation of Kaposi’s sarcoma cells with either one of four different well characterized preparations of pure HCG dimer or any of its two subunits did not alter cellular proliferation suggesting that a contaminant (or degradation product) may be the active agent. Commercial HCG preparations were subfractionated based on molecular size and each fraction was tested with respect to inhibition of KS cell growth, HCG radioreceptor binding and steroidogenic bioactivity. Results demonstrate that the anti-KS activity resides among low molecular weight components, and not in bona fide (macromolecular) HCG. Our study indicates that HCG activity and anti-KS action are separable. Interestingly, the active components in the crude HCG markedly down-regulate AP-1, a complex of transcription factors of the immediate-early response genes associated with cell growth. We conclude that, as yet unidentified molecules, present in the commercial HCG preparations, are responsible for the growth inhibitory effects presumably via the AP-1 signalling pathway.

This article has been cited by other articles:

				S. Malatos, H. Neubert, A. T. Kicman, and R. K. Iles Identification of Placental Transforming Growth Factor-{beta} and Bikunin Metabolites as Contaminants of Pharmaceutical Human Chorionic Gonadotrophin Preparations by Proteomic Techniques Mol. Cell. Proteomics, July 1, 2005; 4(7): 984 - 992. [Abstract] [Full Text] [PDF]

				S. A. Butler and R. K. Iles Ectopic Human Chorionic Gonadotropin {beta} Secretion by Epithelial Tumors and Human Chorionic Gonadotropin {beta}-Induced Apoptosis in Kaposi's Sarcoma: Is There a Connection? Clin. Cancer Res., October 15, 2003; 9(13): 4666 - 4673. [Abstract] [Full Text] [PDF]

				U. Pfeffer, D. Bisacchi, M. Morini, R. Benelli, S. Minghelli, A. Vacca, D. M. Noonan, and A. Albini Human Chorionic Gonadotropin Inhibits Kaposi's Sarcoma Associated Angiogenesis, Matrix Metalloprotease Activity, and Tumor Growth Endocrinology, August 1, 2002; 143(8): 3114 - 3121. [Abstract] [Full Text] [PDF]

				S. K. Manna, A. Mukhopadhyay, and B. B. Aggarwal Human Chorionic Gonadotropin Suppresses Activation of Nuclear Transcription Factor-kappa B and Activator Protein-1 Induced by Tumor Necrosis Factor J. Biol. Chem., April 28, 2000; 275(18): 13307 - 13314. [Abstract] [Full Text] [PDF]

				Z. Darzynkiewicz The Butler Did It: Search for Killer(s) of Kaposi's Sarcoma Cells in Preparations of Human Chorionic Gonadotropin J Natl Cancer Inst, January 20, 1999; 91(2): 104 - 106. [Full Text] [PDF]

				F. Samaniego, J. L. Bryant, N. Liu, J. E. Karp, A. L. Sabichi, A. Thierry, Y. Lunardi-Iskandar, and R. C. Gallo Induction of Programmed Cell Death in Kaposi's Sarcoma Cells by Preparations of Human Chorionic Gonadotropin J Natl Cancer Inst, January 20, 1999; 91(2): 135a - 143a. [Abstract] [Full Text] [PDF]

				J. Bird, X. Li, Z. M. Lei, J. Sanfilippo, M. A. Yussman, and Ch. V. Rao Luteinizing Hormone and Human Chorionic Gonadotropin Decrease Type 2 5{alpha}-Reductase and Androgen Receptor Protein Levels in Women's Skin J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1776 - 1782. [Abstract] [Full Text]